Persomed develops an innovative personalized cell therapy platform which can be widely deployed in any type of solid cancer.
According to the set timeline, Persomed will reach its first major milestone end of next year: a proof of concept phase I clinical study for at least eight metastatic colorectal patients. If all goes well, Persomed aims to expand its pipeline towards other hard-to-treat solid cancers as well that are not responding to the current standard-of-care
Click here to know more!